Method of Enhancing KSHV LANA1 Immunogenicity
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsYuan Chang, Patrick S. Moore
Life of this patent
Estimating the term…
Abstract
An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.
Claims15
A nucleic acid encoding a Kaposi sarcoma associated herpes virus latency associated nuclear antigen amino acid sequence (“KSHV LANA1”) having the amino acid sequence of SEQ ID NO:
- 1, wherein the amino acid sequence is modified by the substitution or deletion of at least one amino acid between amino acids 330 and 914.
A nucleic acid encoding a Kaposi sarcoma associated herpes virus latency associated nuclear antigen amino acid sequence (“KSHV LANA1”) and having the amino acid sequence of SEQ ID NO:
- 1 and a protein destabilization domain, wherein the amino acid sequence is modified by removing or replacing at least one amino acid between amino acid 330 and amino acid 428 of SEQ ID NO:
- 1.
A method of eliciting an immune response to Kaposi sarcoma associated herpes virus latency associated nuclear antigen (“KSHV LANA1”) in a patient comprising introducing into the patient a nucleic acid encoding a Kaposi sarcoma associated herpes virus latency associated nuclear antigen amino acid sequence (“KSHV LANA1”) having the amino acid sequence of SEQ ID NO:
- 1, wherein the amino acid sequence is modified such that 20 to 98 amino acids between amino acids 330 and 428 are deleted.
Dependencies are inferred from the claim text.